Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.48 |
| ▸ | ITGAV | P06756 | 8/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.48 |
| ▸ | SUCNR1 | Q9BXA5 | 11/20 | 0.38 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20141331 | 1.00 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGA2BSUCNR1 | |
| SCHEMBL29797272 | 0.86 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BPDE4D | |
| SCHEMBL20139498 | 0.86 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGA2BPDE4D | |
| SCHEMBL20139800 | 0.82 | ITGB3 (0.44) | ITGB3ITGAVITGB6ITGA2B | |
| SCHEMBL29797221 | 0.82 | ITGB3 (0.44) | ITGB3ITGAVITGB6ITGA2B | |
| SCHEMBL20140268 | 0.82 | ITGB3 (0.73) | ITGB3ITGAVITGB6ITGA2B | |
| SCHEMBL29797431 | 0.82 | ITGB3 (0.73) | ITGB3ITGAVITGB6ITGA2B | |
| SCHEMBL21311604 | 0.80 | SUCNR1 (0.38) | ITGB3ITGAVITGB6ITGA2BSUCNR1 | |
| SCHEMBL20153348 | 0.76 | ITGB3 (0.34) | ITGB3ITGAVITGB6ITGA2BSUCNR1 | |
| SCHEMBL20140217 | 0.76 | ITGB3 (0.41) | ITGB3ITGAVITGB6ITGA2BSUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-110167935-B | 3-substituted propionic acids as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | ITGB3 1/4885ITGAV 3/4885ITGB6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.